Merus released updated clinical data for petosemtamab showing responses across multiple lines of colorectal cancer, signaling potential use beyond its development focus in head and neck tumors. Early results indicate activity that could expand the antibody’s clinical utility; Merus highlighted response rates in first‑line and later settings and signaled plans to pursue additional cohorts and combination strategies. The data will be evaluated against emerging standards for colorectal cancer and could influence partnering or registration decisions depending on durability and safety profiles.